Importance Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway
is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report …

4012 Background: Dysregulation of the MET/HGF pathway is associated with poor
prognosis in GEC. Onartuzumab (O), a monovalent anti-MET antibody, inhibits the MET/HGF …

Abstract Background. The phase II YO28252 study (01590719) examined first-line
onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor …

Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …

Background Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal
antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We …

This phase II trial examined the addition of ramucirumab, a vascular endothelial growth
factor receptor-2 monoclonal antibody, to mFOLFOX6 as front-line therapy for patients with …

5 Background: Trastuzumab (H)+ capecitabine/fluorouracil+ cisplatin is standard of care for
1st-line HER2-positive MGC/GEJC but there is no established HER2-targeted 2nd-line …

Background Although trastuzumab plus chemotherapy is the standard of care for first-line
treatment of HER2-positive advanced gastric cancer, there is no established therapy in the …

4004 Background: RAM, an anti-VEGFR2 monoclonal antibody, improved overall survival
(OS) in 2 phase 3 trials in patients (pts) with previously treated gastric/gastroesophageal …

Background Clinical data showed promising antitumour activity with feasible tolerability for
matuzumab plus epirubicin, cisplatin and capecitabine (ECX) chemotherapy in untreated …